drugset / Trial / NCT01122264

A Study in Patients With Erectile Dysfunction

NCT01122264

Phase 4 Completed 770 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate if treatment in erectile dysfunction with a long-acting drug (Tadalafil) taken once a day or taken as needed results in a longer treatment adherence and better long term outcomes (over 24 weeks), compared with a short-acting drug (Sildenafil Citrate) taken as needed.

Timeline

Start
2010-05
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sildenafil Unknown 25 mg Oral
Comparator Sildenafil Unknown 50 mg Oral
Comparator Sildenafil Unknown 100 mg Oral
Subject Tadalafil Small molecule 2.5 mg Oral
Subject Tadalafil Small molecule 5 mg Oral
Subject Tadalafil Small molecule 10 mg Oral
Subject Tadalafil Small molecule 20 mg Oral

Indications